Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

US biotech Regeneron Pharmaceuticals says that its investigational gene therapy DB-OTO showed clinically-meaningful hearing ...

Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearingSpeech and development ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment ...

Regeneron acquired DB-OTO as part of its $109 million acquisition of Decibel Therapeutics last year. Meanwhile, French biotech Sensorion is running a phase 1/2 trial of its SENS-501 (OTOF-GT ...

Regeneron Pharmaceuticals ... has several advantages over currently approved intravitreal agents. For DB-OTO, our otoferlin gene therapy program for genetic hearing loss, we announced data ...

Regeneron does not undertake any obligation ... several advantages over currently approved intravitreal agents. For DB-OTO, our otoferlin gene therapy program for genetic hearing loss, we ...